Take stock of 12 authorized partnerships, such as Baiji, Howson and other innovative treatments introduced/licensed in July.

In July, china's pharmaceutical companies remained active in licensing deals.
12 Chinese companies agreed to cooperate last month, according to incomplete statistics.
in Baiji Shenzhou, pharmaceutical Gianto, Qilu Pharmaceuticals and other companies to introduce products at the same time, Vantai Bio, Howson Pharmaceuticals, Bai Otai and other Chinese companies have also achieved independent research and development of products licensed out.
, we've taken a look at some of the most closely watched licensing cases to see what innovative treatments and technologies are involved in these transactions.
1, Introducing Party: Baiji Shenzhou Licensing Party: Assembly Biosciences Drug Disease Field: Hepatitis B Baiji Shenzhou obtains three clinical stage core inhibitors ABI-H for the treatment of chronic hepatitis B infection in the Assembly Biosciences research and development pipeline Assembly reserves full rights to the exclusive development and commercialization of 0731, ABI-H2158 and ABI-H3733 in Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan), and Assembly reserves the full rights to its hepatitis B research and development pipeline worldwide, except in those regions.
up to $540 million in advance and milestone payments for the transaction.
all three hepatitis B small molecule candidate drugs are core hepatitis B inhibitors that inhibit multiple steps in the life cycle of hepatitis B, according to the Baiji Shenzhou press release.
Among them, ABI-H0731 is a generation of core inhibitors, and in Phase 2 clinical trials, ABI-H0731 combined nucleotide (acid) analogan reverse transcriptase inhibitor (NrtI) is well tolerated, resulting in statistically significant antiviral activity in inhibitory hepatitis B virus DNA compared to NtrI monotherapy, and may also significantly reduce the level of pre-genome RNA (pgDNA).
ABI-H2158 and ABI-H3733 are two powerful second-generation candidate drugs, respectively, in phase 2 clinical and Phase 1 clinical development stage.
2. Introduction: Drug Acepodia Drug Type: Cell Immunotherapy Drug JW Therapeutics has obtained exclusive priority licensing for clinical and commercialization in the Chinese mainland, Hong Kong and Macau regions through an exclusive priority licensing agreement with Acepodia (Yu Expo Biosurfery).
, ACE1702 is a cell therapy that targets HER2 and can target the expression of HER2 solid tumors by connecting natural killer cells (oNK) with HER2 antibodies, and is now in clinical trials.
according to a press release, Acepodia's isogenic cell therapy platform is based on its proprietary "off-the-shelf" natural killer cells, which have strong anti-tumor activity.
Acepodia's proprietary ACC™ (Antibody Cell Complex) technology adheres antibodies to cell membrane proteins in self-developed oNK cells with therapeutic potential to enhance their ability to kill tumor cells.
3, Introducing Party: Xingxing Pharmaceuticals Licensing: Cytokinetics Drug Type: Myocardial Myoglobin Inhibitor Xingxing Pharmaceuticals and Cytokinetics have entered into an exclusive licensing agreement for the development and commercialization of the next generation of myocardial myoglobin inhibitor CK-274 in Greater China.
under the agreement, Star Pharmaceuticals has pledged to pay an advance payment and an additional $200 million in milestone payments required in the development and commercialization process, as well as a double-digit sales increase for the product in the agreed area.
CK-274 is a new oral small molecule myocardial myoglobin inhibitor, developed independently by Cytokinetics scientists, designed to reduce the high contraction of hypertropic cardiomyopathy (HCM), according to a press release.
in the preclinical model, CK-274 reduces myocardial contraction by binding directly to myocardial myoglobin at a unique and selective variable binding point, thus preventing myoglobulin from contracting.
CK-274 reduces the number of active myocardial protein-myoglobin cross-bridges per tcardiopathy cycle, thereby reducing myocardial contraction.
this mechanism of action may have therapeutic effects on diseases characterized by excessive contraction, such as HCM.
4, Introducer: Reding Pharmaceuticals Licensor: Turning Point Therapeutics Drug Type: ROS1/TRK Inhibitor Reding Pharmaceuticals acquired exclusive development and commercialization rights to Turn Point's main candidate drug, Repotrectinib, in Greater China, with a total of $176 million in advance and milestone payments.
Repotrectinib is a new generation of tyrosine kinase inhibitors (TKI) in development to be developed to treat non-small cell lung cancer and advanced solid tumors caused by cancer-driven gene changes in ROS1 and TRK.
Currently, repotrectinib is conducting a global Phase 2 registration study for adult patients and a Global Phase 1/2 study for children, which shows that the drug in the study has anti-tumor activity and long-lasting response to both patients who have not been treated with TKI and those who have received TKI treatment.
5, Introducer: Saisheng Pharmaceuticals Licensor: EpicentRx Drug Type: TargetING CD47-SIRP Alpha Oncology Immunotherapy Saisheng Pharmaceuticals introduced a tumor immunotherapy RRx-001 from EpiccentRx.
under the agreement, Sesseam Pharmaceuticals is granted exclusive license to jointly develop and commercialize RRx-001 for cancer treatment in Greater China, as well as an unannited advance payment to IdealRx and a milestone of up to $120 million.
addition, Saisheng Pharma has the option to develop RRx-001's application in hepatocellular carcinoma separately in Greater China.
According to a press release, RRx-001 targets CD47-SIRP alpha, which enables tumor-related macrophages (TAM) and other immunosuppressive cells in tumor micro-environments to multipolarize into immunostimus-stimulating dedications and improve tumor blood flow to enhance oxygen supply and drug delivery.
as a potential immunotherapy that transforms "treatment-resistant" tumors into "treatment-sensitive" tumors, RRx-001 can be used as a monotherapy or in combination with other drugs.
, RRx-001 is currently undergoing a Phase 3 clinical trial to treat small cell lung cancer with third-line and above.
addition, EpicentRx plans to explore the effectiveness of the drug in colorectal cancer, brain metastatic lesions and gliomas, leukemia and bone marrow abnormally proplshengening syndromes.
6, Introducer: Qilu Pharmaceuticals Licensor: Sesen Bio Drug Type: Antibody Concatenation Drug (ADC) Qilu Pharmaceuticals entered into an exclusive licensing agreement with Sesen Bio to obtain the latter's exclusive production, development and commercialization interest in the new drug Vicineum (oportuzumab monatox) in Greater China to develop the drug to treat non-intramolytic bladder cancer (NMIBC) types of non-response to BCG.
Sesen Bio reserves the full development and commercialization rights of Vicineum for the treatment of NMIBC in the United States and in other parts of the world except Greater China.
up to $35 million in advance and milestone payments for this transaction.
Vicinium is a next-generation antibody concatenation drug developed using Sesen Bio's proprietary targeted protein therapy platform that targets epCAM antigens on tumor cell surfaces to provide an effective protein load, prosthetic monocytotoxin A (ETA).
Vicinium is connected by a stable genetically engineered peptide to ensure that the payload remains attached until it is internalized by cancer cells, thereby reducing the toxicity risk to healthy tissue and improving safety.
U.S., Vicinium has been granted orphan drug and fast-track qualification by the FDA to treat NMIBC, which is ineffective against BCG immunotherapy.
December 2019, Sesen Bio has initiated a rolling submission to the FDA of Vilinium's Biologics Licensing Application (BLA).
7, Introducer: Hansen Pharmaceuticals Licensor: Topon Biopharmaceutical Type: BCR-ABL Protein Structure Inhibitor Hansen Pharmaceuticals acquired an exclusive development and commercialization interest in Tudor BioTRN-000632 in Greater China, which will retain the development and commercialization of its products in other markets around the world.
under the agreement, Topiology will receive a down payment of not more than $68 million, research and development, registration, sales milestone payments, and future product sales-based fees.
TRN-000632 is a highly active BCR-ABL protein deconstruction inhibitor that is being used to develop chronic myeloid leukemia (CML)-related antenatal disorders.
8, Introducer: Sanofi Pasteur Licensor: Vantage Biopicine Type: Sanofi Bastard, a wholly owned subsidiary of Vantage Bio Sea Creatures is authorized to develop, produce and commercialize the latter's new rota vaccine globally, primarily to prevent childhood diarrhoea caused by the type A rota virus, while Vantek has the right to obtain the above-mentioned authorization from Sanofi Pasteur for the development of a rota vaccine in China.
the total amount of advances and milestones for this transaction amounted to $68 million.
according to the press release, royvirus vaccine is one of the world's major vaccine varieties, the world's market for roytovirus vaccine is mainly mono-priced and multi-priced seedlings.
deal involves a new rotor recombinant protein vaccine that induces high-titration broad-spectrum protective antibodies against a variety of serotypes in animals.
9, Introducer: EQRx Licensor: Howson Pharmaceuticals Drug Type: 3st Generation EGFR-TKI Hansen (Shanghai) Health Technology and Howson Pharmaceuticals enter into a strategic partnership and licensing agreement with EQRx to grant E QRx exclusive license to develop, produce and commercialize the former's third-generation EGFR-TKI amethyni (and any product containing or consisting of amethyni) outside China in the therapeutic areas of cancer, cancer-related and immunoinspicative diseases.
, registration and development milestone payments for this transaction amounted to approximately $100 million.
Aetna, a third-generation EGFR (epiderm growth factor receptor)-TKI (tyrosine kinase inhibitor) developed by Howson Pharmaceuticals, was approved in China in March this year for the treatment of patients with local late stage or metastatic non-small cell lung cancer (NSCLC) who have previously been treated with EGFR-TKI treatment advances and T790M mutation-positive.
it is worth mentioning that this is not only the first Chinese-made third-generation EGFR-TKI to be approved for listing, but also the second third-generation EGFR-TKI to be approved for listing worldwide.
10, Introducing Party: Pharmapark Licensor: Baiotai Drug Type: Golimmapark Anti-Biosecogenic Drug Bairmapark Authorized Pharmapark company in Russia and other CIS countries exclusive commercialization of its Golimmapark anti-bioseal drug BAT2506.
golimumab is an all-humanized anti-tumor necrotic cause of death (TNF-alpha) monoclonal antibody.
under the cooperation agreement, Bai Otai will be responsible for the development of BAT2506 and the commercialization of products to Pharmapark suppliers.
Pharmapark will be responsible for the commercialization of BAT2506 in Russia and other CIS countries.
the fourth quarter of this year, the company expects to launch Phase 3 clinical trials at BAT2506's International Multi-Center and recruit patients in China, Russia and several other countries, according to a press release.
plans to submit its listing application to China's NMPA, European EMA and FDA after completing Phase 3 clinical trials.
11. Introduction: Lingke Pharmaceuticals Licensor: Kobe University, RIKEN Research Institute Drug Types: RAS Inhibitor Lingke Pharmaceuticals announces the signing of an exclusive licensing agreement with Kobe University of Japan and the Japan Institute of Science and Chemistry (RIKEN) to develop RAS inhibitors with new drug action mechanisms (MOA).
According to the press release, Lingke Pharmaceuticals will use its expertise in pharmacology and drug design to develop better RAS inhibitors for the broader range of "non-mediopolytic" RAS mutation-induced malignancies and ultimately clinically effective drugs, based on the results of early structural biology and screening at Kobe University and RIKEN.
12, Introducer: NewG Lab Pharma Licensor: Nirthy Pharma Pharmaceuticals Type: ROS1/NTRK Inhibitors NewG Lab Pharma Korea is licensed by Pharma Pharma to conduct exclusive clinical development and commercialization of the former ROS1/NTRK inhibitor Taletrectinib in the Korean market.
under the agreement, the company will receive a $7 million milestone payment and double-digit royalties, and NewG Lab will be responsible for the development and commercialization of taletrectinib in South Korea, while being allowed to join the drug's ongoing multi-regional Phase 2 clinical trial for patients with ros1/NTRK mutation NSCLC.
Projectrectinib is a new, effective, highly selective next-generation ROS1 and NTRK dual-target small molecule inhibitor that can travel through the blood.